Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.95 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.95 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL9114797 | 1.00 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL42099 | 1.00 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42098 | 1.00 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42100 | 1.00 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL9114800 | 1.00 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL13747483 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL15094315 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL20211416 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42615 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL727412 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1289978-A4 | NOVEL ELECTRON ACCEPTORS FOR POLYMERIC THIN FILM WAVEGUIDE MEDIA | CORNING INC (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1289978-A1 | NOVEL ELECTRON ACCEPTORS FOR POLYMERIC THIN FILM WAVEGUIDE MEDIA | CORNING INCORPORATED (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001098287-A1 | NOVEL ELECTRON ACCEPTORS FOR POLYMERIC THIN FILM WAVEGUIDE MEDIA | CORNING INCORPORATED (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0634999-A4 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS. | — | 1995-02-01 | — | — | EP | disclosed |
| EP-0634999-A1 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | SLC6A4 4754/4885SIGMAR1 3451/4885TAAR1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.